Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $14.0 million.

  • Arcus Biosciences' Share-based Compensation fell 2631.58% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year decrease of 1948.05%. This contributed to the annual value of $76.0 million for FY2024, which is 410.96% up from last year.
  • Arcus Biosciences' Share-based Compensation amounted to $14.0 million in Q3 2025, which was down 2631.58% from $15.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Share-based Compensation high stood at $20.0 million for Q1 2024, and its period low was $12.8 million during Q1 2021.
  • Over the past 5 years, Arcus Biosciences' median Share-based Compensation value was $17.0 million (recorded in 2022), while the average stood at $16.5 million.
  • As far as peak fluctuations go, Arcus Biosciences' Share-based Compensation soared by 26860.2% in 2021, and later crashed by 2631.58% in 2025.
  • Over the past 5 years, Arcus Biosciences' Share-based Compensation (Quarter) stood at $14.3 million in 2021, then rose by 18.99% to $17.0 million in 2022, then increased by 5.88% to $18.0 million in 2023, then decreased by 5.56% to $17.0 million in 2024, then fell by 17.65% to $14.0 million in 2025.
  • Its last three reported values are $14.0 million in Q3 2025, $15.0 million for Q2 2025, and $16.0 million during Q1 2025.